11 completed, 2 unknown. 6 Phase 3, 5 Phase 2, 3 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Unknown 2 |
| Phase 2 | 5 | Completed 3, Unknown 2 |
| Phase 4 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Isoflurophate: new trials by email Literature Review of Isoflurophate trials Research Report on Isoflurophate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 372 | 2019-01-30 | 2025-12-05 |
| Study of Parkinson's Early Stage With Deferiprone Deferiprone, Placebo - Parkinson's Disease | Phase 2 | Completed | ApoPharma | 140 | 2016-10-12 | 2024-04-10 |
| Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects Intravenous deferiprone, Placebo - Asymptomatic HIV Infection | Phase 1 | Completed | ApoPharma | 30 | 2015-06-01 | 2016-06-07 |
| Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration Deferiprone oral solution - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Completed | ApoPharma | 68 | 2014-06-01 | 2020-08-25 |
| Role of Vitamin C to Augment Iron Chelation With DFP or DFX Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2014-04-01 | 2014-03-11 |
| Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Deferiprone, Deferasirox - Chronic Iron Overload | Phase 3 | Completed | Consorzio per Valutazioni Biologiche e Farmacologiche | 435 | 2014-03-17 | 2021-05-04 |
| A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers Deferiprone, Placebo - Healthy Volunteers | Phase 1 | Completed | ApoPharma | 64 | 2013-11-01 | 2014-12-23 |
| An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment Deferiprone - Renal Impairment | Phase 4 | Completed | ApoPharma | 32 | 2013-01-01 | 2014-08-26 |
| An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers Ferriprox® - Hepatic Impairment | Phase 4 | Completed | ApoPharma | 21 | 2013-01-01 | 2014-09-10 |
| Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) Deferiprone oral solution, Placebo - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Completed | ApoPharma | 89 | 2012-12-13 | 2019-07-05 |
| Pharmacokinetic Study of Deferiprone in Paediatric Patients Deferiprone, dose level 1, Deferiprone, dose level 2, Deferiprone, dose level 3 - Chronic Iron Overload | Phase 2 | Completed | Consorzio per Valutazioni Biologiche e Farmacologiche | 23 | 2012-12-01 | 2017-01-11 |
| Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2012-02-01 | 2012-02-06 |
| Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Deferiprone (DFP) and Deferoxamine (DFO), Deferiprone (DFP) - Beta-Thalassemia, Thalassemia Major | Phase 4 | Completed | Azienda Ospedaliera V. Cervello | 213 | 2000-09-01 | 2008-08-13 |
beta-Thalassemia (5) · Pantothenate Kinase-Associated Neurodegeneration (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1) · HIV Infections (1) · Kidney Diseases (1) · Liver Diseases (1) · Parkinson Disease (1) · Renal Insufficiency (1)
ApoPharma (7) · Ain Shams University (2) · Consorzio per Valutazioni Biologiche e Farmacologiche (2) · Azienda Ospedaliera V. Cervello (1) · University Hospital, Lille (1)
Italy (5) · Egypt (4) · United Kingdom (4) · Canada (3) · Germany (3) · United States (3) · Cyprus (2) · France (2) · Albania (1) · Greece (1) · South Africa (1) · Tunisia (1)
Fernando Tricta, MD (4) · Elliott Vichinsky, MD (2) · Thomas Klopstock, MD (2) · Aurelio Maggio, MD (1) · David Devos, MD (1) · David Devos, MD,PhD (1) · Donato Bonifazi, Dr (1) · Giovanni Carlo Del Vecchio (1) · Mohsen S. Elalfy, professour (1) · Nardo Nardocci, MD (1) · Oscar Della Pasqua (1) · Patrick Chinnery, MD (1)
PMID 19236376, PMID 25600572, PMID 31202468, PMID 32470438, PMID 33926431, PMID 37975798, PMID 39973479
2017 (1)